

HUMAN MILK OLIGOSACCHARIDES (HMOS) 2021 Compendium of Studies

With a focus on brain development, immune support, and digestive health.

IMPORTANT NOTICE: Breastfeeding is best for babies and is recommended for as long as possible during infancy.

TABLE OF CONTENTS

HIGHLIGHTED ABBOTT STUDIES

IMMUNE SUPPORT:

2018

Review of the clinical experiences of feeding infants formula containing the human milk oligosaccharide 2'-fucosyllactose.

(<u>Reverri et al., 2018</u>)......13

2016

Similar to those who are breastfed, infants fed a formula containing 2'-fucosyllactose have lower inflammatory cytokines in a randomized controlled trial.

(Goehring et al., 2016)	4
-------------------------	---

2015

Infants fed a lower calorie formula with 2'-FL show growth and 2'-FL
uptake like breast-fed infants.
(<u>Marriage et al., 2015</u>)

Attenuation of food allergy symptoms following treatment with human milk oligosaccharides in a mouse model.

(*Castillo-Courtade et al., 2015*)......16

BRAIN DEVELOPMENT:

2021

Human Milk Levels of 2'-Fucosyllactose and 6'-Sialyllactose are	
Positively Associated with Infant Neurodevelopment and are Not	
Impacted by Maternal BMI or Diabetic Status.	
(<u>Oliveros et al., 2021</u>)	17

2018

Sialic acid and sialylated oligosaccharide supplementation during	
lactation improves learning and memory in rats.	
(<i>Oliveros et al., 2018</i>)	8

2016

Dietary 2'-fucosyllactose enhances operant conditioning and long-term potentiation via gut-brain communication through the vagus nerve in rodents.

2015

Effects of a human milk oligosaccharide, 2'-fucosyllactose, on hippocampal long-term potentiation and learning capabilities in rodents.

TABLE OF CONTENTS (CONT'D)

DIGESTIVE HEALTH:

2017

Human milk oligosaccharides influence intestinal epithelial cell
maturation in vitro.
(<u>Holscher et al., 2017</u>)

2013

Fucosylated but not sialylated milk oligosaccharides diminish colon
motor contractions.
(<i>Bienenstock et al., 2013</i>)
Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes.


REFERENCES:

Alphabetical by Author



Leading the way in HMO research

ABBOTT HAS SUPPORTED MORE THAN 35 HMO-RELATED STUDIES OVER THE PAST 25+ YEARS



* As measured by circulatory inflammatory cytokines in a clinical study of Similac Pro-Advance".


Human milk composition

HMOs: A MAJOR CLASS OF PREBIOTICS FOUND IN HUMAN MILK

Human milk remains the benchmark for infant nutrition, as it contains hundreds of different bioactive compounds. These biologically important compounds support a host of different systems and processes in the developing infant, including healthy microbial colonization in the gut (*Bode, 2012; Walsh, 2020*).

Analysis of human milk composition shows that water is the most abundant liquid. Lactose and fats are the most abundant solid components. Interestingly, HMOs are the third most abundant solid component of human milk, followed by proteins (*Bode, 2019*). HMOs are a unique type of prebiotic that may support gastrointestinal, neurologic, and immune system development in ways other prebiotics cannot (*Goehring, 2014; Ruhaak, 2014; Bode, 2009; Bode, 2012*).

This compendium summarizes selected published scientific studies around HMOs and their important role in infant nutrition.



Categories of HMOs


THERE ARE 3 CATEGORIES OF HMOs-AND EACH PLAYS AN IMPORTANT ROLE

There are 3 categories of HMOs in human milk: acetylated, fucosylated, and sialylated (*Plaza-Diaz, 2018*). The categories vary structurally from one another: acetylated HMOs terminate in N-acetylglucosamine, fucosylated HMOs have a fucose at the terminal position, and sialylated HMOs have a sialic acid at the terminal position (*Walsh, 2020*).

This compendium focuses on 5 of the most abundant HMOs commonly found in human milk within the three categories (*Coppa*, *1999*;

Thurl, 2010; Austin, 2016; Kunz, 2017; McGuire, 2017; Sprenger, 2017; Tonon, 2019).

Because each HMO category is structurally different, emerging research suggests that they support different functions for the immune system, brain development, and digestive health (*Walsh, 2020; Bode, 2012*).



Support for the immune system


HMOs can be thought of as the "conductors of the immune orchestra" because preclinical research suggests that they act as immune cell modulators to help balance immune response—just as a conductor might set a tempo or indicate how loudly or quietly to play music.

If a cytokine balance cannot be established, an excessive proinflammatory reaction or an anti-inflammatory reaction may ensue. A range of clinical sequelae may then follow (*Oberholzer, 2000*).


Preclinical research suggests that HMOs interact with immune cells (dendritic cells, T cells, B cells) and influence expression of pro-

WHITE BLOOD CELL WITHOUT HMOs inflammatory and anti-inflammatory cytokines. HMOs thereby play a role in maintaining immune system homeostasis (*Donovan, 2016*; *Walsh, 2020*).

- In vitro, 2'-FL HMO has been shown to attenuate monocyte activation and modulate the release of cytokines (*Ayechu-Muruzabal, 2018*).
- In a clinical study, 2'-FL HMO was shown to lower the levels of inflammatory mediators, including TNF-α to be more like levels in breastfed infants (*Goehring, 2016*).



WHITE BLOOD CELL WITH HMOs





Support for brain development

Preclinical research suggests that HMOs may play a beneficial role in the brain through communication via **1**) **circulation** and **2**) **the vagus nerve**. (*Oliveros, 2018; Jacobi, 2016; Lis-Kuberka, 2019; Mudd, 2017; Tarr, 2015; Vázquez, 2016; Vázquez, 2015; Wang, 2007; Wang, 2009; Wang, 2012; Krug, 1994; Matthies, 1996; Al-Khafaji, 2020; Kuntz, 2019*).

PATHWAY 1 CIRCULATION

Fucose metabolites, sialic acid, and microbiota-derived metabolites may be absorbed into the bloodstream, where they can travel to the brain to support cognitive development.





PATHWAY 2 VAGUS NERVE

2'-FL and microbiota-derived metabolites may activate the vagus nerve and thus stimulate the developing brain.



CLINICAL OUTCOMES

Human milk concentrations of 2'-FL HMO and 6'-SL HMO have been associated with measures of improved cognitive development outcomes through 24 months of age (<u>Oliveros, 2021</u>; <u>Berger, 2020</u>; <u>Jorgensen, 2021</u>).

Support for digestive health

HMOs act as selective prebiotics that resist digestion by human intestinal enzymes and promote growth of healthy microbiota in the gut to support baby's developing immune system (*Bode, 2012*). HMOs are also thought to play an important role in development of the immune system through several mechanisms in the gut and beyond via systemic absorption (*Bode, 2012*; *Castanys-Muñoz, 2016*; *Stepans, 2006*; *Triantis, 2018*).

SYSTEMIC BENEFITS


A small portion of ingested HMOs are absorbed intact into circulation and are excreted in urine (*Goehring, 2014; Rudloff,* 2012), which may explain some of the reported systemic benefits of HMOs (*Goehring,* 2014; *Goehring, 2016*)

SUPPORT METABOLISM

Feed beneficial bacteria which help synthesize vitamins (*LeBlanc*, 2017)


SUPPORT IMMUNE RESPONSES

Stimulate lymphocytes to produce IgA antibodies (*Kleinman, 2014*)



Support for digestive health (cont'd)

In cell culture, each of the 5 HMOs appears to act as a receptor decoy for specific pathogens, which may help block pathogen adhesion to epithelial cell walls (*Bode, 2012*; *Walsh, 2020*; *Kunz, 2000*; *Newburg, 2005*).



HIGHLIGHTED ABBOTT STUDIES

• IMMUNE SUPPORT

- BRAIN DEVELOPMENT
- DIGESTIVE HEALTH

Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2'-Fucosyllactose

Reverri E, Devitt A, Kajzer J, Baggs G, Borschel M. Nutrients. 2018 Sept;10, 1346: 1-11. doi: 10.3390/nu10101346



BACKGROUND

This review summarized the clinical experiences of feeding infants formula containing the human milk oligosaccharide (HMO) 2'-Fucosyllactose (2'-FL) in healthy babies. HMOs are of interest because they are the third most abundant solid component in breast milk besides lactose and lipids. In particular, 2'-FL is the most prevalent HMO in most mothers' milk. Previous studies have examined HMOs' effect on preventing gastrointestinal and respiratory problems and aiding immunity for infants, and 2'-FL's role in cognitive development, as a prebiotic, preventing infections and inflammation, supporting the immune system and lessening the risk of necrotizing enterocolitis. Recently, 2'-FLs have been synthesized and added to infant formula, and have been evaluated as structurally identical to the 2'-FL found in human milk.

METHODS

This narrative review summarized the clinical experiences of feeding healthy infants formula that was supplemented with 2'-FL. The authors searched databases for studies on infant formulas with 2'-FL being fed to infants. Some of the search terms were 2'-FL HMO, 2'-FL, human milk oligosaccharide, HMO, infant formula and formula.

RESULTS

A systematic review was unable to be conducted due to the limited number of studies with variation in results. However, the authors concluded that standard infant formula with 2'-FL fed to babies was safe, well-tolerated, absorbed and excreted similar to breast milk with 2'-FL. Parents reported less respiratory infections in infants fed formula with 2'-FL compared to the control formula. Also, infants fed with formula containing 2'-FL had immune benefits and improved formula tolerance.

CONCLUSION

The addition of 2'-FL to infant formulas brings them closer to the functionality and composition of breast milk. Several clinical studies reported that babies fed formula with 2'-FL had immune benefits, less parent-reported infections, improved formula tolerance for fussy infants, and efficient excretions.

Similar to Those Who Are Breastfed, Infants Fed a Formula Containing 2'-Fucosyllactose Have Lower Inflammatory Cytokines in a Randomized Controlled Trial

Goehring K, Marriage BJ, Oliver JS, Wilder JA, Barrett EG, Buck RH. J Nutr. 2016 Dec;146(12):2559-2566. doi: 10.3945/jn.116.236919



BACKGROUND

Breastfed infants have fewer infections than formula-fed babies. The human milk oligosaccharides (HMOs) in breast milk, in particular, have been shown to help with immune functions such as gut maturation, immune responses, prebiotic effects and antimicrobial activities. This study investigated how the HMO 2'-fucosyllactose (2'-FL) in feeding formulas effected immune function in healthy term infants.

METHODS

Between April 2013 and January 2014, this study was conducted as part of a larger study, as a randomized, double-blind, controlled growth and tolerance study with healthy infants of singleton birth at 28 sites in the United States. The babies were enrolled by 5 days of life and were exclusively fed formula (*n*=317) or breastfed (*n*=107) from enrollment to 4 months old. The formula-fed babies were randomly assigned one of three formulas, all of which contained 2.4 g total oligosaccharides/L [control: galacto-oligosaccharides only (GOS), GOS + 0.2 or 1.0 g 2'-FL/L]. At six weeks, blood samples were drawn from the infants, and peripheral blood mononuclear cells (PBMCs) were isolated for examination and cytokine concentrations were measured in plasma and in ex vivo-stimulated culture supernatants.

RESULTS

There were no significant differences between the feeding groups at birth. However, breastfed infants and babies fed any of the experimental formulas with 2'-FL had less concentrations of plasma inflammatory cytokines than infants fed the control formula. The ex vivo respiratory syncytial virus (RSV)-induced cultures showed that the control-fed group had significantly higher percentages of TNF-*a* and IFN-*y* than breastfed babies. Control-fed and breastfed infants had similar cytokine production in supernatants from phytohemagglutininstimulated PBMCs.

CONCLUSION

The study indicated that infants fed formula with 2'-FL showed lower plasma and ex vivo inflammatory cytokine profiles, similar to breastfed babies. Formulas with 2'-FL support the immune system and regulation, reducing reports of respiratory infections like RSV.

Infants Fed a Lower Calorie Formula With 2'-FL Show Growth and 2'-FL Uptake Like Breastfed Infants

Marriage B, Buck R, Goehring K, Oliver J, Williams J. *Journal of Pediatric Gastroenterology and Nutrition*. 2015 December; 61: 649-658. doi: 10:1097/MPG.00000000000889



BACKGROUND

Human milk provides many benefits to breastfed infants, such as reduced risk of otitis media, gastrointestinal and respiratory tract diseases, obesity and diabetes. This study evaluated the growth and tolerance of babies fed three infant formulas with a caloric density similar to human milk. Two of the formulas were supplemented with 2'-fucosyllactose (2'-FL), a human milk oligosaccharide (HMO), to better quantify the role of HMOs and to study the uptake of HMOs.

METHODS

From April 2013 to January 2014, this prospective, randomized, controlled growth and tolerance study was conducted with healthy, full-term infants who were enrolled by 5 days of age for 119 days. A smaller group of parents agreed to biological sampling for their babies that included urine, stool and blood collection, while breastfeeding mothers provided human milk samples. Formula-fed infants were given one of the three formulas, which all contained 64.3 kcal/dL (19 kcal/fl oz) and galactooligosaccharides (GOS). Two of the experimental formulas were supplemented with different amounts of 2'-FL (at 0.2 and 1.0 g/L). The fourth group was only fed breast milk. Infants were seen at five clinic visits at 14, 28, 42, 84 and 119 days. Their growth was measured, and diet and clinical histories were taken. In the subset group of babies, 2'-FL concentration was tested in their blood and urine samples at 42 and 119 days, and in breastfed infants at 42 days.

RESULTS

At enrollment, there were no significant differences among the feeding groups for age, sex, weight, length or head circumference at birth. The groups showed no significant differences in mean weight, length or head circumference during the study, as well. In addition, the formulas were all well tolerated and led to similar average stool consistency, number of stools per day and percent of feedings associated with spitting up or vomit. Formulas with 2'-FL were well tolerated, and absorbed and excreted similar to breastfed babies.

CONCLUSION

Infants fed formula with a similar caloric density and 2'-FL amount as breast milk grew at a similar pace to breastfed babies. The 2'-FL was well tolerated and absorbed.

Attenuation of Food Allergy Symptoms Following Treatment with Human Milk Oligosaccharides in a Mouse Model

Castillo-Courtade L, Han S, Lee S, Mian FM, Buck R, Forsythe P. Allergy. 2015 May; 1346: 1-12. doi: 10.1111/all.12650



BACKGROUND

Allergic diseases, such as asthma, eczema and food allergies, have significantly increased in the past 30 years, with the World Health Organization even calling them an epidemic. Patients clearly need more effective therapeutic approaches. This study examines the role of two human milk oligosaccharides (HMOs), the neutral 2'-fucosyllactose (2'-FL) and acidic 6'-sialyllactose (6'-SL), and lactose on the symptoms and immune responses to food allergies.

METHODS

Mice were sensitized with oral ovalbumin (OVA) to induce anaphylactic symptoms. Then, 2'-FL, 6'-SL or lactose was administered to OVA-sensitized mice to gauge their treatment ability. Sham-sensitized mice were controls. To test mast cell functions response to HMOs, bone marrow-derived mast cells in vitro were induced for an immune reaction (an IgE-mediated degranulation) and measured for their response to 2'-FL and 6'-SL. In another experiment, mice were given 2'-FL, 6'-SL or lactose for either 5 days, 3 days or an hour before an antigen challenge to measure the mast-cell-dependent passive cutaneous anaphylaxis (PCA) reaction.

RESULTS

Oral treatment with 2'-FL or 6'-SL significantly reduced an OVAinduced intestinal allergy, decreasing diarrhea and hypothermia symptoms. The HMOs also both lessened the amount of mast cell protease-1 (mMCP-1) released from mice's mucosal mast cells in serum, while lactose had no significant effect on the food allergy symptoms or mMCP-1 release. 2'-FL and 6'-SL treatments also reduced the number of mast cells in the colon. However, the HMOs had no effect on the levels of antigens in OVA-sensitized mice. The 2'-FL and 6'-SL treatments were associated with increases in the CD4+ CD25+ IL-10+ cell populations in the mice's Peyer's patches and mesenteric lymph nodes. In addition, the HMOs also reduced the PCA response, which suggests that 2'-FL and 6'-SL stabilize mast cells.

CONCLUSION

Both 2'-FL and 6'-SL can reduce the risk of developing a food allergy, and lessen its symptoms.

Human Milk Levels of 2'-Fucosyllactose and 6'-Sialyllactose Are Positively Associated With Infant Neurodevelopment and Are Not Impacted by Maternal BMI or Diabetic Status

Oliveros E, Martín M, Torres-Espínola F, Segura-Moreno M, Ramírez M, Santos A, Buck R, Rueda R, Escudero M, Catena A, Azaryah H, Campoy C. *Journal of Nutrition & Food Sciences*. 2021; 4(1), 1-11.



BACKGROUND

While human milk offers multiple benefits to infants, its composition is constantly changing due to maternal conditions. In addition, little is known about how maternal factors or the environment may influence human milk oligosaccharides (HMOs) composition. To learn more, the concentrations of 2'-fucosyllactose (2'-FL) and 6'-sialyllacatose (6'-SL) in human milk and their role on infant neurodevelopment were compared with results from neurodevelopment assessments of babies born to mothers from a previous study, "Role of nutrition and maternal genetics on the programming of development of fetal adipose tissue" (PREOBE Study).

METHODS

Ultra-high performance liquid chromatography-MS/MS (UHPLC-MS/ MS) was used to analyze 82 human milk samples collected 1 month postpartum from the PREOBE study, and determine 2'-FL and 6'-SL concentrations. The samples came from overweight, obese, normal weight and gestational diabetic mothers. To evaluate the relationship between 2'-FL and 6'-SL concentrations and infants' neurodevelopment at 6 months and 18 months (through the Bayley Scales of Infant Development), Pearson correlation and multivariate linear regression analysis were conducted.

RESULTS

All of the study groups had 6'-SL and 2'-FL in their milk samples, while some mothers had low or high 2'-FL concentrations in their milk. There was a positive correlation between 6'-SL concentrations and composite cognitive scores for babies at 18 months old, and a trend was noted for 6'-SL concentrations and motor skills. For 2'-FL, a positive trend was associated with 2'-FL concentrations and motor scores at 6 months of age for infants, but no significant connections were made when low and high 2'-FL groups were assessed separately.

CONCLUSION

The amount of 6'-SL and 2'-FL in human milk was not affected by preconceptional maternal body mass index (pBMI) or gestational diabetes mellitus. 6'-SL levels in human milk were associated with infant neurodevelopment. 2'-FL concentrations were connected to positive motor scores of infants at 6 months of age, but only when evaluating low and high 2'-FL milk samples together. Both 6'-SL and 2'-FL levels in human milk correlated to infant cognitive development.

Sialic Acid and Sialylated Oligosaccharide Supplementation During Lactation Improves Learning and Memory in Rats

Oliveros E, Vázquez E, Barranco A, Ramírez M, Gruart A, Delgado-García J, Buck R, Rueda R., Martín M. *Nutrients*. 2018 October; 10, 1519, 1-16. doi: 10.3390/nu10101519



BACKGROUND

The human milk oligosaccharides (HMOs) in human milk, including sialyloligosaccharides, are reported to assist with optimal development and maturation of the immune system, besides being prebiotics. Sialic acids' (Sias) connection to improved cognitive functions has been shown in studies with rodents and pigs, although the mechanism of action hasn't been determined yet. For this study, rat pups were given Sia in free form as N-acetylneuraminic acid (Neu5Ac) or conjugated as 6'-sialyllactose (6'-SL) to see if early Sia supplementation plays a role during neural development, and were evaluated later with behavioral tests and electrophysiological measurements.

METHODS

A group of rat pups were given an oral supplementation of Neu5Ac, while another group received the same molar amount of Sia as 6'-SL. Control pups were given water. After weaning, the pups' brains were examined or another set was given classical behavioral tests such as the Novel Object Recognition Test (NORT) and Y maze tests. Then, for one year the pups were given a standard chow diet. After one year, the male pups were evaluated for long-term potentiation (LTP) measurements and females were administered psychological tests to study long-term effects of learning and memory. Their brain samples were analyzed to determine Sia content as adults.

RESULTS

Adult male rats who received 6'-SL during lactation performed better on behavioral assessments and had a significant response in LTP compared to controls and the Neu5Ac group. Animals that received Sia supplementation, 6'-SL and Neu5Ac, spent longer amounts of time exploring novel objects, scored the best on the Y maze task and performed better on the IntelliCage system test.

CONCLUSION

Animals that received Sia, particularly 6'-SL, during lactation, had improved scores in behavior and electrophysiological analysis, as well as long-term cognitive development.

Dietary 2'-Fucosyllactose Enhances Operant Conditioning and Long-Term Potentiation via Gut-Brain Communication Through the Vagus Nerve in Rodents

Vázquez E, Barranco A, Ramírez M, Gruart A, Delgado-García J, Jimenez M, Buck R, Rueda R. *PloS ONE*. 2016 November; 11(11), 1-14 doi: 10.1371/journal.pone.0166070



BACKGROUND

Among breastfeeding's many benefits, it leads to higher performance on intelligence tests later in life for breastfed children compared to formula fed children. One of the main components of human milk is human milk oligosaccharides (HMOs), of which 2'-fucosyllactose (2'-FL) is thought to positively influence the central nervous system (CNS) through the gut-brain axis (GBA), specifically the vagus nerve. This study measured the effects of 2'-FL or fucose on rats in vivo hippocampal long-term potentiation (LTP), and 2'-FL's effect on the cognitive skills and hippocampal LTP in rats that undergo bilateral subdiaphragmatic vagotomy.

METHODS

The rats were prepared for the experiments and divided into 3 groups: 2'-FL, fucose and control. 2'-FL and fucose were orally administered to the rats. Two weeks before the feeding treatments, vagotomy was performed. The animals in the experiments were implanted with stimulating and recording electrodes in the hippocampus, and recording tetrodes. One week after surgery, the electrophysiological studies started, with different pulses applied to Schaffer collaterals. In another experiment, a high frequency protocol was employed to evoke LTP. Animals were also trained and tested in basic Skinner box modules.

RESULTS

Chronic delivery of 2'-FL, but not fucose, enhanced LTP, while vagotomy inhibited the effect of 2'-FL on LTP. 2'-FL also improved cognitive performance in the Skinner box, but a bilateral vagotomy eliminated those conditioning results.

CONCLUSION

The afferent vagus nerve was involved in the modulatory effect of ingested 2'-FL on brain function. Furthermore, bilateral vagotomy prevented the beneficial effects of 2'-FL on LTP. Animals fed a diet supplemented with 2'-FL showed an enhanced LTP and better results on associative learning related tests. The oral administration of 2'-FL benefited brain function and cognition in rats via the vagus nerve. Dietary 2'-FL improved cognitive abilities through the pathway of the GBA and vagus nerve connections in rodents.

HIGHLIGHTED ABBOTT STUDIES: BRAIN DEVELOPMENT

2015

Effects of a Human Milk Oligosaccharide, 2'-Fucosyllactose, on Hippocampal Long-Term Potentiation and Learning Capabilities in Rodents

Vázquez E, Barranco A, Ramírez M, Gruart A, Delgado-García J, Martínez-Lara E, Blanco S, Martín M, Castanys E, Buck R, Prieto P, Rueda R. *Journal of Nutritional Biochemistry*. 2015; 26, 455-465. doi: 10.1016/j.jnutbio.2014.11.016



BACKGROUND

Breastfed infants are associated with significantly higher cognitive development scores than formula-fed babies. Human milk is hard to replicate, however, with its more than 150 identified human milk oligosaccharides (HMOs) structures. Several studies with rats, mice and chicks have evaluated the role of fucose on brain networks. This study further examined how the HMO, 2'-fucosyllactose (2'-FL), effects synaptic plasticity and learning capabilities in rodents.

METHODS

Mice and rats were prepared for the electrophysiological study and implanted with stimulating and recording electrodes in the hippocampus. For most of the experiments, 2'-FL was administered orally. The rodents were tested on input/output curves and longterm potentiation (LTP) after chronic administration of 2'-FL. The IntelliCage testing system evaluated spontaneous and learning behavior of radiofrequency identification (RFID)-tagged mice in a home cage environment. Rats were tested with a fixed-ratio of food pellets in the Skinner box, and were also assessed with immunohistochemistry procedures. Animals were also chronically control fed 2'-FL before their brains were assessed with biochemical techniques.

RESULTS

2'-FL has a positive effect on learning and memory in rodents. The study showed that feeding conscious mice and rats a diet with 2'-FL increased LTP at the hippocampus, enhanced memory consolidation, spatial learning and associative learning. It also increased several molecular brain markers, such as postsynaptic density protein 95.

CONCLUSION

All of the measurable results of this study can be attributed to 2'-FL as it was the only difference in the composition of the rodents' diets. Administering 2'-FL to rodents had a positive effect on their hippocampal LTP and performance in different learning tests. This is the first evidence of the active role 2'-FL plays in cognitive outcomes.

HIGHLIGHTED ABBOTT STUDIES: DIGESTIVE HEALTH

2017

Human Milk Oligosaccharides Influence Intestinal Epithelial Cell Maturation In Vitro

Holscher H, Bode L, Tappenden K. *Journal of Pediatric Gastroenterology and Nutrition*. 2017 February; 64(2), 296-301. doi: 10.1097/MPG.00000000001274



BACKGROUND

The human milk oligosaccharides (HMOs) in breast milk provide many benefits to infants, including prebiotic and immunologic development and may induce gut maturation. As such, they are being researched as potential ingredients in infant formulas. Previously it has been reported that HMOs affect cell dynamics and encourage epithelial cell differentiation in vitro. To our knowledge, this is the first study to assess the impact of specific combinations of HMOs of commercial interest on intestinal epithelial cell function, which is critical to gut maturation.

METHODS

An in vitro epithelial model was created of the small intestinal cryptvillus axis with preconfluent HT-29, preconfluent Caco-2Bbe and postconfluent Caco-2Bbe cells. These cell cultures were seeded and allowed to adhere before incubation with HMO treatments for 72 hours. The treatment groups contained synthetic 3'-sialyllactose (3'-SL), 6'-siallylactose (6'-SL) and 2'-fucosyllactose (2'-FL) at low and high doses, combined in pairs or groups of three at both high and low doses, and controls (culture medium, 4g/L pooled HMO and lipopolysaccharide).

RESULTS

The three HMOs in the study performed as well as the more diverse, substantial pooled HMO treatment. This suggests that only a few commercially viable oligosaccharides may be needed to replicate the same results as a full set of oligosaccharides from human milk. Preconfluent HT-29 cultures were decreased by high doses of individual HMOs (P<0.05), combined HMOs (P<0.05) and pooled HMO (P<0.001). Preconfluent Caco-2Bbe cell proliferations were significantly reduced by pools of individual low and high treatments with 3'-SL and 6'-SL, combinations of 2 or 3 high-dose HMOs and total HMO. Postconfluent Caco-2Bbe cells treated with pooled HMO had decreased apoptosis and necrosis, amongst other results.

CONCLUSION

Specific, commercially viable HMOs in infant formula have the potential to support gastrointestinal tract development. Individual and combined treatments with 2'-FL, 3'-SL and 6'-SL reduced proliferation in preconfluent transformed small intestinal cell lines HT-29 and Caco-2Bbe. Decreased proliferation was also associated with enhanced differentiation. This combination suggests that HMOs support gut maturation.

HIGHLIGHTED ABBOTT STUDIES: DIGESTIVE HEALTH

2013

Fucosylated but Not Sialylated Milk Oligosaccharides Diminish Colon Motor Contractions

Bienenstock J, Buck R, Linke H, Forsythe P, Stanisz A, Kunze W. PLoS ONE. 2013 October; 8(10), 1-9. doi: 10.1371/journal.pone.0076236



BACKGROUND

The benefits of human milk oligosaccharides (HMOs) in breast milk to babies has been studied by many researchers, but more is left to learn about their biological effects. In particular, HMOs seem to effect colonic cell lines through promoting the growth of different types of gut bacteria, such as bifidobacteria and lactic acid bacteria. This study evaluates if HMOs like 2'-fucosyllactose (2'-FL) and 3-fucosyllactose (3-FL) can control gut motor contractions.

METHODS

The study used a standardized ex vivo colon preparation with mice; the HMOs, 2'-FL, 3-FL and 6'-sialyllactose (6'-SL), came from bacterial synthesis. Peak pressures (PPr) were applied to gut motor complexes, and the difference between baseline and maximum pressure reached were measured. HMOs were applied to each experiment only once, because their concentration did not fully wash out. To confirm the results of the PPr recordings, a video imaging system recorded peristalsis of colonic motor contractions.

RESULTS

Only 2'-FL and 3-FL effected PPr, decreasing the frequency of gut contractions and velocity. No significant effects were observed with the other HMOs: 6'-SL, 3'-sialyllactose, lacto-N-neotetraose and galactooligosaccharides. Lactose was the negative control in this experiment.

CONCLUSION

HMOs with fucosylated molecules, such as 2'-FL and 3-FL, calmed colon contractions within 5 to 15 minutes. Fucose seems to play a significant role in reducing gut motility. It is worth exploring if fucosylated HMOs can reduce the pain associated with disordered motility, such as infantile colic. The results also showed potential for fucosylated oligosaccharides to positively effect cognition and memory.

HIGHLIGHTED ABBOTT STUDIES: DIGESTIVE HEALTH

2013

Utilization of Major Fucosylated and Sialylated Human Milk Oligosaccharides by Isolated Human Gut Microbes

Yu Z, Chen C, Newburg D. *Glycobiology* 2013 September; 23(11), 1281-1292. doi: 10.1093/glycob/cwt065



BACKGROUND

Breast milk is full of human milk oligosaccharides (HMOs), which are considered prebiotics because they stimulate the growth of several bifidobacteria of the infant gut microbiota. HMOs cannot be digested by infants' intestines. But this actually allows them to greater nourish infants, as the majority of ingested oligosaccharides are able to be used as a source of energy and enrich gut bacteria. However, most gut bacteria need more than just HMOs to grow. This study measured the degree to which bacteria are able to use fucosylated HMOs and sialylated HMOs for their growth.

METHODS

The human intestinal microbiota has 25 major isolates. In this study, each of the 25 major isolates was fed individual major fucosylated and sialylated HMOs in an anaerobic culture. Then, specific HMOs were assessed for their effect on the growth and metabolic products of individual microbiota bacteria.

RESULTS

The major fucosylated HMOs, 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL) and lactodifucotetraose (LDFT), affected the growth of gut microorganisms. The induction of 2'-FL and acid production led to significant changes: growth (r=0.442, P=0.027) and pH (r=0.514, P=0.009), as well as changes in organic acid production correlated with changes in pH (r=0.739, P=0.001). The major sialylated human milk trisaccharides, 3'-sialyllactose (3'-SL) and 6'-siallactose (6'-SL), also affected the growth of gut-related microorganisms, but not as much as 2'-FL and 3-FL.

CONCLUSION

Major fucosylated HMOs can strongly stimulate gut bacteria (bifidobacteria and bacteroides), reduce pH and create an acidic environment in their role as prebiotics.

REFERENCES



ABBOTT-SPONSORED STUDIES: ALPHABETICAL BY AUTHOR

B

Bienenstock J, Buck RH, Linke H, Forsythe P, Stanisz AM, Kunze WA. **Fucosylated but not sialylated milk oligosaccharides diminish colon motor contractions.** *PLoS ONE*. 2013;8(10):e76236. doi:10.1371/journal. pone.0076236

С

Castillo-Courtade L, Han S, Lee S, Mian FM, Buck R, Forsythe P. Attenuation of food allergy symptoms following treatment with human milk oligosaccharides in a mouse model. *Allergy*. 2015;70(9):1091-1102.

Chow J, Panasevich MR, Alexander D, et al. **Fecal metabolomics of healthy breastfed versus formula-fed infants before and during in vitro batch culture fermentation.** *J Proteome Res.* 2014;13(5):2534-2542.

D

Duska-McEwen G, Senft AP, Ruetschilling TL, Barrett EG, Buck RH. **Human milk oligosaccharides enhance innate immunity to respiratory syncytial virus and influenza in vitro.** *Food Nutr Sci.* 2014;5:1387-1398. doi:10.4236/fns.2014.514151

Ε

Erney RM, Malone WT, Skelding MB, et al. **Variability of human milk neutral oligosaccharides in a diverse population**. *J Pediatr Gastroenterol Nutr*. 2000;30(2):181-192.

F

Farhin S, Wong A, Delungahawatta T, et al. **Restraint stress** induced gut dysmotility is diminished by a milk oligosaccharide (2'-fucosyllactose) in vitro. *PLoS ONE*. 2019;14(4):e0215151. doi:10.1371/journal.pone.0215151

G

Goehring KC, Kennedy AD, Prieto PA, Buck RH. **Direct evidence for the presence of human milk oligosaccharides in the circulation of breastfed infants.** *PLoS ONE*. 2014;9(7):e101692. doi:10.1371/journal. pone.0101692

Goehring KC, Marriage BJ, Oliver JS, Wilder JA, Barrett EG, Buck RH. **Similar to those that are breastfed, infants fed a formula containing 2'-fucosyllactose have lower inflammatory cytokines in a randomized controlled trial.** *J Nutr.* 2016;146(12):2559-2566.

Η

He Y, Lawlor NT, Newburg DS. **Human milk components modulate toll-like receptor-mediated inflammation.** *Adv Nutr.* 2016;7(1): 102-111.

Holscher HD, Davis SR, Tappenden KA. **Human milk oligosaccharides influence maturation of human intestinal Caco-2Bbe and HT-29 cell lines.** *J Nutr.* 2014;144(5):586-591.

Holscher HD, Bode L, Tappenden KA. **Human milk oligosaccharides influence intestinal epithelial cell maturation in vitro.** *J Pediatr Gastroenterol Nutr.* 2017;64(2):296-301.

Κ

Kajzer J, Oliver J, Marriage B. **Gastrointestinal tolerance of formula supplemented with oligosaccharides.** *FASEB J*. 2016;30(suppl 1):671.4. doi:10.1096/fasebj.30.1_supplement.671.4

Kuntz S, Kunz C, Borsch C, et al. **Metabolic fate and distribution of** 2'-fucosyllactose: direct influence on gut microbial activity but not on brain. *Mol Nutr Food Res.* 2019;63(13):e1900035. doi:10.1002/ mnfr.201900035

ABBOTT-SPONSORED STUDIES: ALPHABETICAL BY AUTHOR (CONT'D)

Μ

Marriage BJ, Buck RH, Goehring KC, Oliver JS, Williams JA. **Infants fed a lower calorie formula with 2'-FL show growth and 2'-FL uptake like breastfed infants.** *J Pediatr Gastroentrol Nutr.* 2015;61(6):649-658.

Morrin ST, Buck RH, Farrow M, Hickey RM. **Milk-derived antiinfectives and their potential to combat bacterial and viral infection.** *J Funct Foods.* 2021;81:104442. doi:10.1016/j.jff.2021.104442

Ν

Noll AJ, Yu Y, Lasanajak Y, et al. **Human DC-SIGN binds specific human milk glycans.** *Biochem J*. 2016;473(10):1343-1353.

0

Oliveros E, Ramirez M, Vázquez E, et al. **Oral supplementation of** 2'-fucosyllactose during lactation improves memory and learning in rats. *J Nutr Biochem*. 2016;31:20-27.

Oliveros E, Vázquez E, Barranco A, et al. **Sialic acid and sialylated oligosaccharide supplementation during lactation improves learning and memory in rats.** *Nutrients.* 2018;10(10):1519.

Oliveros E, Martín MJ, Torres-Espínola FJ, et al. **Human milk levels of** 2'-fucosyllactose and 6-sialyllactose are positively associated with infant neurodevelopment and are not impacted by maternal BMI or diabetic status. *J Nutr Food Sci.* 2021;4:024.

Ρ

Prieto PA, Mukerji P, Kelder B, et al. **Remodeling of mouse milk glycoconjugates by transgenic expression of a human glycosyltransferase.** *J Biol Chem.* 1995;270(49):29515-29519. Prieto PA. **In vitro and clinical experiences with a human milk oligosaccharide, Lacto-N-neoTetraose, and fructooligosaccharides.** *Foods Food Ingredients J Jpn.* 2005;210(11):1018-1030.

R

Ramirez-Farias C, Baggs GE, Marriage BJ. **Growth, tolerance, and compliance of infants fed an extensively hydrolyzed infant formula with added 2'-fucosyllactose (2'-FL) human milk oligosaccharide.** *Nutrients.* 2021;13(1):186.

Reverri EJ, Devitt AA, Kajzer JA, Baggs GE, Borschel MW. **Review** of the clinical experiences of feeding infants formula containing the human milk oligosaccharide 2'-fucosyllactose. *Nutrients*. 2018;10(10):1346. doi:10.3390/nu10101346

Reverri EJ, Baggs GE, Xie W, et al. **Parent reported health parameters of infants fed HMO containing infant formula, infant formula without HMO, or human milk.** Abstract presented at: North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Online Conference. November 1-7, 2020.

Reverri EJ, Xie W, DeWitt T, et al. **Parent reported health of young children fed HMO containing growing up milk vs no growing up milk.** Abstract presented at: North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Online Conference. November 1-7, 2020.

Rudloff S, Kuntz S, Borsch C, et al. **Fucose as a cleavage product of** 2'-fucosyllactose does not cross the blood-brain barrier in mice. *Mol Nutr Food Res.* 2021. doi:10.1002/mnfr.202100045

ABBOTT-SPONSORED STUDIES: ALPHABETICAL BY AUTHOR (CONT'D)

S

Santos-Fandila A, Zafra-Gómez A, Vázquez E, Navalón A, Rueda R, Ramírez M. **Ultra high performance liquid chromatography-tandem mass spectrometry method for the determination of soluble milk glycans in rat serum.** *Talanta.* 2014;118:137-146.

Sodhi CP, Wipf P, Yamaguchi Y, et al. **The human milk** oligosaccharides 2'-fucosyllactose and 6'-sialyllactose protect against the development of necrotizing enterocolitis by inhibiting toll-like receptor 4 signaling. *Pediatr Res.* 2021;89(1):91-101.

Т

Thongaram T, Hoeflinger JL, Chow J, Miller MJ. **Human milk** oligosaccharide consumption by probiotic and human-associated bifidobacteria and lactobacilli. *J Dairy Sci.* 2017;100(10):7825-7833.

V

Van den Abbeele P, Duysburgh C, Vázquez E, Chow J, Buck R, Marzorati M. **2'-fucosyllactose alters the composition and activity of gut microbiota from formula-fed infants receiving complementary feeding in a validated intestinal model.** *J Funct Foods*. 2019;61:103484. doi:10.1016/j.jff.2019.103484

Vázquez E, Barranco A, Ramírez M, et al. **Effects of a human milk oligosaccharide, 2'-fucosyllactose, on hippocampal long-term potentiation and learning capabilities in rodents.** *J Nutr Biochem.* 2015;26(5):455-465.

Vázquez E, Barranco A, Ramirez M, et al. **Dietary 2'-fucosyllactose** enhances operant conditioning and long-term potentiation via gut-brain communication through the vagus nerve in rodents. *PLoS ONE*. 2016;11(11):e0166070. Vázquez E, Santos-Fandila A, Buck R, Rueda R, Ramirez M. **Major human milk oligosaccharides are absorbed into the systemic circulation after oral administration in rats.** *Br J Nutr*. 2017;117(2):237-247.

Vester Boler BM, Rossoni Serao MC, Faber TA, et al. **In vitro fermentation characteristics of select nondigestible oligosaccharides by infant fecal inocula.** *J Agric Food Chem.* 2013;61(9):2109-2119.

W

Werts AD, Fulton WB, Ladd MR, et al. **A novel role for necroptosis in the pathogenesis of necrotizing enterocolitis.** *Cell Mol Gastroenterol Hepatol.* 2020;9(3):403-423.

Υ

Yu Z-T, Chen C, Newburg DS. **Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes.** *Glycobiology*. 2013;23(11):1281-1292.

Z

Zehra S, Khambati I, Vierhout M, Firoz Mian M, Buck R, Forsythe P. Human milk oligosaccharides attenuate antigen–antibody complex induced chemokine release from human intestinal epithelial cell lines. *J Food Sci.* 2018;83(2):499-508.

REFERENCED STUDIES: ALPHABETICAL BY AUTHOR

Al-Khafaji AH, Jepsen SD, Christensen, KR, et al. The potential of human milk oligosaccharides to impact the microbiota-gut-brain axis through modulation of the gut microbiota. *Journal of Functional Foods*. 2020;74. doi:10.1016/j.jff.2020.104176

Austin S, De Castro CA, Bénet T, et al. Temporal change of the content of 10 oligosaccharides in the milk of Chinese urban mothers. *Nutrients*. 2016;8(6):346.

Ayechu-Muruzabal V, van Stigt AH, Mank M, et al. Diversity of human milk oligosaccharides and effects on early life immune development. *Frontiers in Pediatrics*. 2018;6:239.

Berger PK, Plows JF, Jones RB, et al. Human milk oligosaccharide 2'-fucosyllactose links feedings at 1 month to cognitive development at 24 months in infants of normal and overweight mothers. *PLOS One*. 2020;15(2):e0228323.

Bode L. Human milk oligosaccharides: prebiotics and beyond. *Nutrition Reviews*. 2009;67(suppl 2):S183-S191.

Bode L. Human milk oligosaccharides: every baby needs a sugar mama. *Glycobiology*. 2012;22(9):1147-62.

Bode L. Human milk oligosaccharides: next-generation functions and questions. *In: Human Milk: Composition, Clinical Benefits and Future Opportunities.* Karger Publishers; 2019:191-201.

Castanys-Muñoz E, Martin MJ, & Vazquez E, et al. Building a beneficial microbiome from birth. *Advances in Nutrition*. 2016;15;7(2):323-30.

Coppa GV, Pierani P, Zampini L, et al. Oligosaccharides in human milk during different phases of lactation. *Acta Paediatrica*. 1999;88:89-94.

Donovan SM, & Comstock, SS. Human milk oligosaccharides influence neonatal mucosal and systemic immunity. *Annals of Nutrition and Metabolism*. 2016;69(suppl 2):41-51.

Jacobi SK, Yatsunenko T, Li D, et al. Dietary isomers of sialyllactose increase ganglioside sialic acid concentrations in the corpus callosum and cerebellum and modulate the colonic microbiota of formula-fed piglets. *Journal of Nutrition*. 2016;146(2):200–208.

Jorgensen JM, Young R, Ashorn P, et al. Associations of human milk oligosaccharides and bioactive proteins with infant growth and development among Malawian mother-infant dyads. *American Journal of Clinical Nutrition*. 2021;113(1):209-220.

Kleinman RE, Greer FR, eds. *Pediatric Nutrition: Policy of the American Academy of Pediatrics*. 7th ed. American Academy of Pediatrics, 2014.

Krug M, Wagner M, Staak S, et al. Fucose and fucose-containing sugar epitopes enhance hippocampal long-term potentiation in the freely moving rat. *Brain Research*. 1994;643(1-2):130–135.

Kunz C, Meyer C, Collado MC, et al. Influence of gestational age, secretor, and lewis blood group status on the oligosaccharide content of human milk. *Journal of Pediatric Gastroenterology and Nutrition*. 2017;64(5):789-798.

Kunz C, Rudloff S, Baier W, et al. Oligosaccharides in human milk: structural, functional, and metabolic aspects. *Annual Review of Nutrition*. 2000;20(1):699-722.

LeBlanc JG, Chain F, Martín R, et al. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. *Microbial Cell Factories*. 2017;16:79. doi: 10.1186/s12934-017-0691-z

REFERENCED STUDIES: ALPHABETICAL BY AUTHOR (CONT'D)

Lis-Kuberka J & Orczyk-Pawiłowicz M. Sialylated oligosaccharides and glycoconjugates of human milk. The impact on infant and newborn protection, development and well-being. *Nutrients*. 2019;11(2):306.

Matthies H, Staak S, & Krug M. Fucose and fucosyllactose enhance in-vitro hippocampal long-term potentiation. *Brain Research*. 1996;725(2):276–280.

McGuire MK, Meehan CL, & McGuire MA. What's normal? Oligosaccharide concentrations and profiles in milk produced by healthy women vary geographically. *American Journal of Clinical Nutrition*. 2017;105(5):1086-1100.

Mudd AT, Fleming SA, Labhart B, et al. Dietary sialyllactose influences sialic acid concentrations in the prefrontal cortex and magnetic resonance imaging measures in corpus callosum of young pigs. *Nutrients*. 2017;9(12):1297.

Newburg DS, Ruiz-Palacios G, & Morrow A. Human milk glycans protect infants against enteric pathogens. *Annual Review of Nutrition*. 2005;25:37-58.

Oberholzer A, Oberholzer C, & Moldawer LL. Cytokine signalingregulation of the immune response in normal and critically ill states. *Critical Care Medicine*. 2000;28(suppl 4):N3-N12.

Plaza-Díaz J, Fontana L, & Gil A. Human milk oligosaccharides and immune system development. *Nutrients*. 2018;10(8):1038.

Rudloff S & Kunz C. Milk oligosaccharides and metabolism in infants. 2012. *Advances in Nutrition*. 3:398S–405S.

Ruhaak LR, Stroble C, & Underwood M. Detection of milk oligosaccharides in plasma of infants. *Analytical and Bioanalytical Chemistry*. 2014;406(24):5775-5784. doi: 10.1007/s00216-014-8025-z Sprenger N, Lee LY, De Castro CA, et al. Longitudinal change of selected human milk oligosaccharides and association to infants' growth, an observatory, single center, longitudinal cohort study. *PLOS One*. 2017;12(2):e0171814.

Stepans MB, Wilhelm SL, Hertzog M, et al. Early consumption of human milk oligosaccharides is inversely related to subsequent risk of respiratory and enteric disease in infants. *Breastfeeding Medicine: The Official Journal of the Academy of Breastfeeding Medicine.* 2006;1:207–215.

Tarr AJ, Galley JD, Fisher SE, et al. The prebiotics 3' Sialyllactose and 6' Sialyllactose diminish stressor-induced anxiety-like behavior and colonic microbiota alterations: Evidence for effects on the gut–brain axis. *Brain, Behavior, and Immunity*. 2015;50:166–177.

Thurl S, Munzert M, Boehm G, et al. Systematic review of the concentrations of oligosaccharides in human milk. *Nutrition Reviews*. 2017;75(11):920-933.

Thurl S, Munzert M, Henker J, et al. Variation of human milk oligosaccharides in relation to milk groups and lactational periods. *British Journal of Nutrition*. 2010;104(9):1261-1271.

Tonon KM, Miranda A, Abrão ACF, et al. Validation and application of a method for the simultaneous absolute quantification of 16 neutral and acidic human milk oligosaccharides by graphitized carbon liquid chromatography–electrospray ionization–mass spectrometry. *Food Chemistry*. 2019;274:691-697.

Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. *Nature*. 2012;489:242-249. doi:10.1038/ nature11552

REFERENCED STUDIES: ALPHABETICAL BY AUTHOR (CONT'D)

Triantis V, Bode L, & Van Neerven RJ. Immunological effects of human milk oligosaccharides. *Frontiers in Pediatrics*. 2018;6:190.

Walsh C, Lane JA, van Sinderen D, et al. From lab bench to formulated ingredient: Characterization, production, and commercialization of human milk oligosaccharides. *Journal of Functional Foods*. 2020;72:104074.

Wang B. Molecular mechanism underlying sialic acid as an essential nutrient for brain development and cognition. *Advances in Nutrition*. 2012;3(3):465S–472S. doi:10.3945/an.112.001875

Wang B. Sialic acid is an essential nutrient for brain development and cognition. *Annual Review of Nutrition*. 2009;29:177–222.

Wang B, Yu B, Karim M, et al. Dietary sialic acid supplementation improves learning and memory in piglets. *American Journal of Clinical Nutrition*. 2007;85(2):561–569.



IMPORTANT NOTICE: Breastfeeding is best for babies and is recommended for as long as possible during infancy.